Last reviewed · How we verify
ASA 81mg
At a glance
| Generic name | ASA 81mg |
|---|---|
| Also known as | Acetylsalicylic acid 81mg |
| Sponsor | University of Manitoba |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hypertension
- Vaginal Spotting
- Fetal concerns
- Infection
- COVID
- headaches
- Emesis
- Nose bleeds
- Allergic reaction
Key clinical trials
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- Trial to Determine Effective Aspirin Dose in COPD (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Body Weight, Aspirin Dose and Pro-resolving Mediators (PHASE4)
- Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube (EARLY_PHASE1)
- Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial (PHASE3)
- Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA). (PHASE4)
- Postpartum Low-Dose Aspirin and Preeclampsia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASA 81mg CI brief — competitive landscape report
- ASA 81mg updates RSS · CI watch RSS
- University of Manitoba portfolio CI